Treatment pathways, switches, and inappropriate treatment during invasive pulmonary aspergillosis: real-world experiences from a global research network study

Despite advancements in diagnosing and treating invasive pulmonary aspergillosis (IPA), there is limited knowledge of real-world treatment pathways and medication switches. We queried the TrinetX global research network database and identified 5,410 patients diagnosed with IPA. The most common initial treatments were voriconazole (49%), fluconazole (11%), and posaconazole (7%). Most patients remained on voriconazole (80%) or isavuconazole (78%) throughout the treatment duration. Switches were more frequent for those initially treated with fluconazole, echinocandins, or posaconazole.

Automated summary

Despite advancements in diagnosing and treating invasive pulmonary aspergillosis (IPA), limited knowledge of real-world treatment pathways and medication switches exists. A study on 5,410 IPA patients found that the most common initial treatments were voriconazole (49%), fluconazole (11%), and posaconazole (7%). The majority of patients remained on voriconazole (80%) or isavuconazole (78%) throughout treatment, while switches were more frequent for those initially treated with fluconazole, echinocandins, or posaconazole.